References
-
1.
Salt WB, 2nd. Nonalcoholic fatty liver disease (NAFLD): a comprehensive review. J Insur Med. 2004;36(1):27-41. [PubMed ID: 15104027].
-
2.
Hajiaghamohammadi AA, Ziaee A, Oveisi S, Masroor H. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study. Hepat Mon. 2012;12(8). e6099. [PubMed ID: 23087748]. https://doi.org/10.5812/hepatmon.6099.
-
3.
Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. Am J Public Health. 1996;86(5):726-8. [PubMed ID: 8629727].
-
4.
The CONSORT Statement. Available from: http://www.consort-statement.org/consort-statement/overview0/.
-
5.
Jamali R, Pourshams A, Amini S, Deyhim MR, Rezvan H, Malekzadeh R. The upper normal limit of serum alanine aminotransferase in Golestan Province, northeast Iran. Arch Iran Med. 2008;11(6):602-7. [PubMed ID: 18976029].